0001209191-23-028316.txt : 20230509
0001209191-23-028316.hdr.sgml : 20230509
20230509170735
ACCESSION NUMBER: 0001209191-23-028316
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230501
FILED AS OF DATE: 20230509
DATE AS OF CHANGE: 20230509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Howe Jolanda
CENTRAL INDEX KEY: 0001974200
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38981
FILM NUMBER: 23903255
MAIL ADDRESS:
STREET 1: C/O MIRUM PHARMACEUTICALS, INC.
STREET 2: 950 TOWER LANE, SUITE 1050
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001759425
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831281555
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 1050
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 650-667-4085
MAIL ADDRESS:
STREET 1: 950 TOWER LANE, SUITE 1050
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2023-05-01
0
0001759425
Mirum Pharmaceuticals, Inc.
MIRM
0001974200
Howe Jolanda
C/O MIRUM PHARMACEUTICALS, INC.
950 TOWER LANE, SUITE 1050
FOSTER CITY
CA
94404
0
1
0
0
SVP, Global Controller
Common Stock
1769
D
Stock Option (right to buy)
2.94
2029-03-11
Common Stock
57900
D
Stock Option (right to buy)
6.27
2029-05-13
Common Stock
50000
D
Stock Option (right to buy)
19.24
2030-01-09
Common Stock
25000
D
Stock Option (right to buy)
19.19
2031-01-06
Common Stock
25000
D
Stock Option (right to buy)
15.87
2032-01-05
Common Stock
22500
D
Stock Option (right to buy)
19.98
2032-06-30
Common Stock
18750
D
Stock Option (right to buy)
23.48
2033-01-30
Common Stock
21250
D
Restricted Stock Units
Common Stock
2500
D
Restricted Stock Units
Common Stock
3125
D
Restricted Stock Units
Common Stock
5315
D
Performance Restricted Stock Units
Common Tcok
1563
D
1/4th of the 62,500 shares originally subject to the option vested one year after February 28, 2019, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter.
1/4th of the shares vested one year after April 12, 2019 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
1/4th of the shares vested one year after January 10, 2020 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
1/4th of the shares vested one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
1/4th of the shares vested one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
1/4th of the shares vest one year after July 1, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date) and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
The restricted stock units vest in a series of three successive equal annual installments beginning January 6, 2023. 1,250 shares vested January 6, 2023 and the remaining 2,500 shares vest ratably on January 6, 2024 and January 6, 2025.
Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
The restricted stock units vest in a series of three successive equal annual installments beginning July 1, 2023.
The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024.
On March 9, 2021, the reporting person was granted performance-based restricted stock units ("PSUs"), which vest upon the satisfaction of certain performance criteria. On September 29, 2021, such performance criteria were met. 1,562 shares subject to the PSUs vested on September 29, 2021, and 1,563 shares vest on June 30, 2023.
/s/ Judit Ryvkin, Attorney-in-Fact
2023-05-08
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of Christopher Peetz and Judit Ryvkin of Mirum Pharmaceuticals, Inc. (the
"Company"), signing individually, the undersigned's true and lawful
attorney-in-fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 4th day of May, 2023.
/s/ Jody Howe
(Signature)
Jody Howe
(Name: Printed or Typed)